

## Tables

Table	#	Item	Page
Table	1.01:	Stock and Flow of RRT, Malaysia 1995 – 2004	2
Table	1.02:	New Dialysis Acceptance Rate and New Transplant Rate per	3
Table	1.03:	RRT Prevalence Rate per million population 1995 – 2004	4
Table	2.1.1:	Stock and flow – Dialysis Patients 1995 – 2004	6
Table	2.1.2:	Dialysis Treatment Rate per million population 1995 – 2004	6
Table	2.1.3:	Dialysis Treatment Rate by State, per million state population 1995-2004	6
Table	2.2.1:	Number of dialysis centres, HD machines and treatment capacity by sector, Dec 2004	7
Table	2.2.2:	Number of dialysis centres, number of HD machines and treatment capacity, HD capacity to patients ratio and number of dialysis patients by state in Dec 2004	9
Table	2.2.3:	Growth in HD capacity and HD patients in Private, NGO and MOH sectors, 1999-2004	11
Table	2.3.1(a):	Dialysis Treatment Rate by Gender, per million male or female population 1995–2004	12
Table	2.3.1(b):	Gender distribution of Dialysis Patients 1995-2004	12
Table	2.3.2(a):	Dialysis Treatment Rate by Age Group, per million age group population 1995 – 2004	13
Table	2.3.2(b):	Percentage Age Distribution of Dialysis Patients 1995 – 2004	14
Table	2.3.3:	Method and Location of Dialysis 1995 – 2004	15
Table	2.3.4:	Funding for Dialysis Treatment 1995 – 2004	16
Table	2.3.5:	Distribution of Dialysis Patients by Sector 1995 – 2004	17
Table	2.4.1:	Primary Renal Disease 1995– 2004	18
Table	3.1.1:	Deaths on Dialysis 1995 – 2004	20
Table	3.1.2:	Causes of Death on Dialysis 1995 - 2004	21
Table	3.2.1:	Unadjusted patient survival by Dialysis modality, 1995-2004	22
Table	3.2.2:	Unadjusted patient survival by year of entry, 1995-2004	23
Table	3.2.3:	Unadjusted patient survival by age, 1995-2004	24
Table	3.2.4:	Unadjusted patient survival by Diabetes status, 1995-2004	25
Table	4.1:	Cumulative distribution of QL-Index score in relation to Dialysis modality, All Dialysis patients 1997-2004	27
Table	4.2:	Cumulative distribution of QL-Index score in relation to Diabetes mellitus, All Dialysis patients 1997-2004	27
Table	4.3:	Cumulative distribution of QL-Index score in relation to Gender, All Dialysis patients 1997-2004	28
Table	4.4:	Cumulative distribution of QL-Index score in relation to Age, All Dialysis patients 1997-2004	28
Table	4.5:	Cumulative distribution of QL-Index score in relation to Year of entry, HD patients 1997-2004	29
Table	4.6:	Cumulative distribution of QL-Index score in relation to Year of entry, CAPD patients 1997-2004	29
Table	4.7:	Work related rehabilitation in relation to Modality, Dialysis patients 1997-2004	30
Table	4.8:	Work related rehabilitation in relation to Year of Entry, HD patients 1997-2004	30
Table	4.9:	Work related rehabilitation in relation to Year of Entry, CAPD patients 1997-2004	30
Table	5.01:	Stock and Flow of Paediatric Renal Replacement Therapy 1990-2004	32
Table	5.02:	Paediatric Dialysis and Transplant Treatment Rates per million age-group population 1990-2004	33
Table	5.03:	Dialysis Treatment Rate by State, per million state age group population, 1990-2004	34
Table	5.08:	Primary Renal Disease 1990-2004	36
Table	5.09:	Types of Renal Transplant 1990-2004	36
Table	5.10:	Patient Survival by Modality of RRT, 1990-2004	37
Table	5.11:	Dialysis Technique Survival by Modality, 1990-2004	38
Table	5.12:	Transplant Graft Survival 1990-2004	38
Table	6.1.1:	Treatment for Anemia, HD patients 1997-2004	40
Table	6.1.2:	Treatment for Anemia, CAPD patients 1997-2004	40
Table	6.1.3:	Variation in Erythropoietin utilization (% patients) among HD centres, 2004	41
Table	6.1.4:	Variation in Erythropoietin utilization (% patients) among CAPD centres, 2004	41
Table	6.1.5:	Variation in median weekly Erythropoietin dose (u/week) among HD centres 2004	42
Table	6.1.6:	Variation in median weekly Erythropoietin dose (u/week) among CAPD centres 2004	42
Table	6.1.7:	Variation in use of blood transfusion (% patients) among HD centres, 2004	43

Table	6.1.8:	Variation in use of blood transfusion (% patients) among CAPD centres, 2004	43
Table	6.2.1:	Distribution of Serum Ferritin without Erythropoietin, HD patients 1997–2004	44
Table	6.2.2:	Distribution of Serum Ferritin without Erythropoietin, CAPD patients 1997–2004	44
Table	6.2.3:	Distribution of Serum Ferritin on Erythropoietin, HD patients 1997 – 2004	45
Table	6.2.4:	Distribution of Serum Ferritin on Erythropoietin, CAPD patients 1997 – 2004	45
Table	6.2.5:	Distribution of transferrin saturation without Erythropoietin, HD patients 1997-2004	46
		Distribution of transferrin saturation without Erythropoietin, CAPD patients 1997-2004	
Table	6.2.6:		46
Table	6.2.7:	Distribution of transferrin saturation on Erythropoietin, HD patients 1997 – 2004	47
Table	6.2.8:	Distribution of transferrin saturation on Erythropoietin, CAPD patients 1997 – 2004	47
Table	6.2.9:	Variation in iron status outcomes among HD centres 2004	48
	(a)	Median serum ferritin among patients on erythropoietin	48
	(b)	Proportion of patients on erythropoietin with serum ferritin $\geq$ 100 ng/ml	48
	(c)	Median transferrin saturation among patients on erythropoietin	49
	(d)	Proportion of patients on erythropoietin with transferrin saturation $\geq$ 20%	49
Table	6.2.10:	Variation in iron status outcomes among CAPD centres 2004	50
	(a)	Median serum ferritin among patients on erythropoietin	50
	(b)	Proportion of patients on erythropoietin with serum ferritin $\geq$ 100 ng/ml	50
	(c)	Median transferrin saturation among patients on erythropoietin	51
	(d)	Proportion of patients on erythropoietin with transferrin saturation $\geq$ 20%	51
Table	6.3.1:	Distribution of Haemoglobin Concentration without Erythropoietin, HD patients 1997 – 2004	52
Table	6.3.2:	Distribution of Haemoglobin Concentration without Erythropoietin, CAPD patients 1997– 2004	52
Table	6.3.3:	Distribution of Haemoglobin Concentration on Erythropoietin, HD patients 1997 – 2004	53
Table	6.3.4:	Distribution of Haemoglobin Concentration on Erythropoietin, CAPD patients 1997 – 2004	53
Table	6.3.5:	Variation in Haemoglobin outcomes among HD centres 2004	54
	(a)	Median haemoglobin level among patients on erythropoietin	54
	(b)	Proportion of patients on erythropoietin with haemoglobin level > 10 g/dL	54
	(c)	Proportion of patients on erythropoietin with haemoglobin level > 11 g/dL	55
Table	6.3.6:	Variation in Haemoglobin outcomes among CAPD centres 2004	55
	(a)	Median haemoglobin level among patients on erythropoietin	55
	(b)	Proportion of patients on erythropoietin with haemoglobin level > 10 g/dL	56
	(c)	Proportion of patients on erythropoietin with haemoglobin level > 11 g/dL	56
Table	7.1.1:	Distribution of serum Albumin (g/L), HD patients 1997-2004	58
Table	7.1.2:	Distribution of serum Albumin (g/L), CAPD patients 1997-2004	59
Table	7.1.3:	Variation in Proportion of patients with serum albumin $\geq$ 40g/L among HD centres 2004	60
Table	7.1.4:	Variation in Proportion of patients with serum albumin $\geq$ 40g/L among CAPD centres 2004	61
Table	7.2.1:	Distribution of BMI, HD patients 1997-2004	62
Table	7.2.2:	Distribution of BMI, CAPD patients 1997-2004	63
Table	7.2.3:	Variation in Proportion of patients with BMI $\geq$ 18.5 among HD centres 2004	64
Table	7.2.4:	Variation in Proportion of patients with BMI $\geq$ 18.5 among CAPD centres 2004	65
Table	8.1.1:	Distribution of Pre dialysis Systolic Blood Pressure (mmHg), HD patients 1997-2004	67
Table	8.1.2:	Distribution of Pre dialysis Systolic Blood Pressure (mmHg), CAPD patients 1997-2004	68
Table	8.1.3:	Distribution of Pre dialysis Diastolic Blood Pressure (mmHg), HD patients 1997-2004	69
Table	8.1.4:	Distribution of Pre dialysis Diastolic Blood Pressure (mmHg), CAPD patients 1997-2004	70
Table	8.1.5:	Variation in BP control among HD centres 2004	71
	(a)	Median Systolic blood pressure (mmHg) among HD patients	71
	(b)	Median Diastolic blood pressure (mmHg) among HD patients	72
	(c)	Proportion of HD patients with Pre dialysis Blood Pressure $\leq$ 140/90 mmHg	72
Table	8.1.6:	Variation in BP control among CAPD centres 2004	73
	(a)	Median Systolic blood pressure (mmHg) among CAPD patients	73
	(b)	Median Diastolic blood pressure (mmHg) among CAPD patients	74
	(c)	Proportion of CAPD patients with Pre dialysis Blood Pressure $\leq$ 140/90 mmHg	74
Table	8.2.1:	Distribution of serum Cholesterol (mmol/L), HD patients 1997-2004	75

Table	8.2.2:	Distribution of serum Cholesterol (mmol/L), CAPD patients 1997-2004	75
Table	8.2.3:	Distribution of serum Triglyceride (mmol/L), HD patients 1997-2004	76
Table	8.2.4:	Distribution of serum Triglyceride (mmol/L), CAPD patients 1997-2004	77
Table	8.2.5:	Variation in dyslipidaemia among HD centres 2004	78
	(a)	Median serum cholesterol level among HD patients	78
	(b)	Proportion of patients with serum cholesterol < 5.3 mmol/L	78
	(c)	Median serum triglyceride level among HD patients	79
	(d)	Proportion of patients with serum triglyceride < 2.1 mmol/L	79
Table	8.2.6:	Variation in dyslipidaemia among CAPD centres 2004	80
	(a)	Median serum cholesterol level among HD patients	80
	(b)	Proportion of patients with serum cholesterol < 5.3 mmol/L	80
	(c)	Median serum triglyceride level among CAPD patients	81
	(d)	Proportion of patients with serum triglyceride < 2.1 mmol/L	81
Table	9.1.1:	Treatment for Renal Bone Disease, HD patients 1997-2004	83
Table	9.1.2:	Treatment for Renal Bone Disease, CAPD patients 1997-2004	83
Table	9.2.1:	Distribution of corrected Serum Calcium, HD patients 1997-2004	84
Table	9.2.2:	Distribution of corrected Serum Calcium, CAPD patients 1997-2004	84
Table	9.2.3:	Distribution of Serum Phosphate, HD patients 1997-2004	85
Table	9.2.4:	Distribution of Serum Phosphate, CAPD patients 1997-2004	85
Table	9.2.5:	Distribution of corrected calcium x phosphate product, HD patients 1997-2004	86
Table	9.2.6:	Distribution of corrected calcium x phosphate product, CAPD patients 1997-2004	86
Table	9.2.7:	Variation in corrected serum calcium levels among HD centres, 2004	87
	(a)	Median serum calcium level among HD patients	87
	(b)	Proportion of patients with serum calcium 2.2 to 2.6 mmol/L	88
Table	9.2.8:	Variation in corrected serum calcium levels among CAPD centres, 2004	89
	(a)	Median serum calcium level among CAPD patients	89
	(b)	Proportion of patients with serum calcium 2.2 to 2.6 mmol/L	89
Table	9.2.9:	Variation in serum phosphate levels among HD centres, 2004	90
	(a)	Median serum phosphate level among HD patients	90
	(b)	Proportion of patients with serum phosphate $\leq$ 1.6 mmol/L	90
Table	9.2.10:	Variation in serum phosphate levels among CAPD centres, 2004	91
	(a)	Median serum phosphate level among CAPD patients	91
	(b)	Proportion of patients with serum phosphate $\leq$ 1.6 mmol/L	91
Table	9.2.11:	Variation in corrected calcium x phosphate product among HD centres, 2004	92
	(a)	Median corrected calcium x phosphate product among HD patients	92
	(b)	Proportion of patients with corrected calcium x phosphate product < 4.5 mmol <sup>2</sup> /L <sup>2</sup>	92
Table	9.2.12:	Variation in corrected calcium x phosphate product among CAPD centres, 2004	93
	(a)	Median corrected calcium x phosphate product among CAPD patients	93
	(b)	Proportion of patients with corrected calcium x phosphate product < 4.5 mmol <sup>2</sup> /L <sup>2</sup>	93
Table	10.1:	Prevalence of positive HBsAg and positive Anti-HCV at annual survey, HD patients 1997-2004	96
Table	10.2:	Prevalence of positive HBsAg and positive Anti-HCV at annual survey, CAPD patients 1997-2004	96
Table	10.3:	Variation in Proportion of patients with positive HBsAg at annual survey among HD centres, 2004	97
Table	10.4:	Variation in Proportion of patients with positive HBsAg at annual survey among CAPD centres, 2004	97
Table	10.5:	Variation in Proportion of patients with positive anti-HCV at annual survey among HD centres, 2004	98
Table	10.6:	Variation in Proportion of patients with positive anti-HCV at annual survey among CAPD centres, 2004	99
Table	11.1.1:	Vascular Access on Haemodialysis, 1997-2004	101
Table	11.1.2:	Difficulties reported with Vascular Access, 1997-2004	101
Table	11.1.3:	Complications reported with Vascular Access, 1997-2004	102
Table	11.2.1:	Blood Flow Rates in HD Units, 1997– 2004	103
Table	11.2.2:	Number of HD Sessions per week, 1997 – 2004	104
Table	11.2.3:	Duration of HD, 1997 – 2004	104
Table	11.2.4:	Dialyser membrane types in HD Units, 1997 – 2004	105
Table	11.2.5:	Dialyser Reuse Frequency in HD Units, 1997- 2004	106
Table	11.2.6:	Dialysate Buffer used in HD Units, 1997 – 2004	107
Table	11.2.7:	Distribution of prescribed KT/V, HD patients 1997-2004	107

Table	11.2.8:	Variation in HD prescription among HD centres 2004	108
	(a)	Median blood flow rates in HD patients	108
	(b)	Proportion of patients with blood flow rates > 250 ml/min	109
	(d)	Median prescribed KT/V in HD patients	110
	(e)	Proportion of patients with prescribed KT/V $\geq 1.3$	111
Table	11.3.1:	Unadjusted technique survival by Dialysis modality, 1995-2004	112
Table	11.3.2:	Unadjusted technique survival by year of entry, 1995-2004	113
Table	11.3.3:	Unadjusted technique survival by age, 1995-2004	114
Table	11.3.4:	Unadjusted technique survival by Diabetes status, 1995-2004	115
Table	12.1.1:	Chronic Peritoneal Dialysis Regimes, 1997-2004	117
Table	12.1.2:	CAPD Connectology, 1997-2004	117
Table	12.1.3:	CAPD Number of Exchanges per day, 1997-2004	118
Table	12.1.4:	CAPD Volume per Exchange, 1997– 2004	118
Table	12.2.1:	Distribution of delivered KT/V, CAPD patients 2003-2004	119
Table	12.2.2:	Variation in proportion of patients with KT/V $\geq 2.0$ per week among CAPD centres 2004	119
Table	12.2.3:	Peritoneal transport status by PET D/P creatinine at 4 hours, new PD patients 2003-2004	120
Table	12.2.4:	Peritoneal transport status by PET D/P creatinine at 4 hours, prevalent PD patients 2003-2004	120
Table	12.3.1:	Unadjusted technique survival by Dialysis modality, 1995-2004	121
Table	12.3.2:	Unadjusted technique survival by year of entry, 1995-2004	122
Table	12.3.3:	Unadjusted technique survival by age, 1995-2004	123
Table	12.3.4:	Unadjusted technique survival by Diabetes status, 1995-2004	124
Table	12.3.5:	Unadjusted technique survival by Gender, 1995-2004	124
Table	12.4.1:	Variation in peritonitis rate (pt-month/epi) among CAPD centres 2004	125
Table	12.4.2:	Causative organism in PD peritonitis, 2000-2004	126
Table	12.4.3:	Factors influencing peritonitis rate, 2000-2004	126
Table	13.1.1:	Stock and Flow of Renal Transplantation, 1975-2004	129
Table	13.1.2:	New transplant rate per million population (pmp), 1975-2004	130
Table	13.1.3:	Transplant prevalence rate per million population (pmp), 1975-2004	130
Table	13.2.1:	Renal Transplant Recipients' Characteristics, 1975-2004	131
Table	13.2.2:	Primary causes of end stage renal failure, 1975-2004	132
Table	13.3.1:	Type of Renal Transplantation, 1975-2004	133
Table	13.3.2:	Biochemical data, 2004	134
Table	13.3.3:	Medication data, 2004	134
Table	13.4.1:	Post transplant complications, 2004	135
Table	13.4.2:	Transplant Patients Death Rate and Graft Loss, 1975-2004	136
Table	13.4.3:	Causes of Death in Transplant Recipients, 1975-2004	137
Table	13.4.4:	Causes of Graft Failure, 1975-2004	138
Table	13.4.5:	Patient survival, 1993-2004	139
Table	13.4.6:	Graft survival, 1993-2004	139
Table	13.4.7:	Patient survival by type of transplant, 1993-2004	140
Table	13.4.8:	Graft survival by type of transplant, 1993-2004	141
Table	13.4.9:	Patient survival by year of transplant (Living related transplant, 1993-2004)	141
Table	13.4.10:	Graft survival by year of transplant (Living related transplant, 1993-2004)	142
Table	13.4.11:	Patient survival by year of transplant (Commercial cadaver transplant, 1993-2004)	143
Table	13.4.12:	Graft survival by year of transplant (Commercial cadaver transplant, 1993-2004)	143